ArticleScientific reports2024

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy.

Zhendong Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.